Genesis and Dynamics of Atherosclerotic Lesions: Implications for Early Detection

Atherosclerosis is a diffuse pathological process characterized by the deposition of lipid and other blood-borne material within the arterial wall of almost all vascular territories. Cholesterol accumulation plays a central role in atherogenesis. It is the result of an imbalance between cholesterol influx and efflux. The disease progresses silently with focal clinical manifestation due to plaque rupture with superimposed thrombus: atherothrombosis. It has been shown that the atherosclerotic plaque composition rather than the degree of arterial stenosis can be the determinant of rupture. This has led to the search for new imaging techniques that can provide information about plaque composition. Ultrasound measurements of carotid and aortic wall thickness are an accurate ‘noninvasive’ technique that permits correlation with clinical events. Magnetic resonance imaging can evaluate in detail the arterial anatomy of almost all vascular territories. Multidetector computed tomography recently emerged for measuring luminal stenosis, coronary calcium, and even the extent of non-calcified coronary plaque volume. Next future is the molecular imaging based on the knowledge of molecular mechanisms involved in the genesis and progression of atherosclerotic lesions and the contrast agent able to identify different molecules and/or cells in the target zone.

[1]  V. Fuster,et al.  Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. , 1990, The Journal of clinical investigation.

[2]  G J Boerma,et al.  Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). , 1995, Circulation.

[3]  Werner Moshage,et al.  Detection of Coronary Artery Stenoses by Contrast-Enhanced, Retrospectively Electrocardiographically-Gated, Multislice Spiral Computed Tomography , 2001, Circulation.

[4]  V. Fuster,et al.  Lipid Lowering by Simvastatin Induces Regression of Human Atherosclerotic Lesions: Two Years’ Follow-Up by High-Resolution Noninvasive Magnetic Resonance Imaging , 2002, Circulation.

[5]  M. E. Kooi,et al.  Accumulation of Ultrasmall Superparamagnetic Particles of Iron Oxide in Human Atherosclerotic Plaques Can Be Detected by In Vivo Magnetic Resonance Imaging , 2003, Circulation.

[6]  Paul Schoenhagen,et al.  Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.

[7]  Milind Y Desai,et al.  Statin-Induced Cholesterol Lowering and Plaque Regression After 6 Months of Magnetic Resonance Imaging–Monitored Therapy , 2004, Circulation.

[8]  S. Achenbach,et al.  Detection of Calcified and Noncalcified Coronary Atherosclerotic Plaque by Contrast-Enhanced, Submillimeter Multidetector Spiral Computed Tomography: A Segment-Based Comparison With Intravascular Ultrasound , 2003, Circulation.

[9]  Zahi A. Fayad,et al.  Molecular, cellular and functional imaging of atherothrombosis , 2004, Nature Reviews Drug Discovery.

[10]  Jeannie K. Lee,et al.  Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins , 2004, Circulation.

[11]  V. Fuster,et al.  In Vivo 16-Slice, Multidetector-Row Computed Tomography for the Assessment of Experimental Atherosclerosis: Comparison With Magnetic Resonance Imaging and Histopathology , 2004, Circulation.

[12]  V. Fuster,et al.  Caspase-3 and Tissue Factor Expression in Lipid-Rich Plaque Macrophages: Evidence for Apoptosis as Link Between Inflammation and Atherothrombosis , 2004, Circulation.

[13]  Martin J Graves,et al.  Identification of Culprit Lesions After Transient Ischemic Attack by Combined 18F Fluorodeoxyglucose Positron-Emission Tomography and High-Resolution Magnetic Resonance Imaging , 2005, Stroke.

[14]  V. Fuster,et al.  Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. , 2005, Journal of the American College of Cardiology.

[15]  Aloke V. Finn,et al.  Atherosclerotic Plaque Progression and Vulnerability to Rupture: Angiogenesis as a Source of Intraplaque Hemorrhage , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[16]  Deepak L. Bhatt,et al.  International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. , 2006, JAMA.

[17]  Yoram Rudy,et al.  From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. , 2006, The American journal of cardiology.

[18]  V. Fuster,et al.  Neovascularization in human atherosclerosis. , 2006, Current molecular medicine.

[19]  D. Berman,et al.  From Vulnerable Plaque to Vulnerable Patient—Part III: Executive Summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force Report , 2006 .

[20]  D. Rader,et al.  Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? , 2006, Circulation.

[21]  J. Badimón,et al.  The role of high-density lipoprotein cholesterol in the prevention and possible treatment of cardiovascular diseases. , 2006, Current molecular medicine.

[22]  Raimund Erbel,et al.  Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. , 2006, JAMA.

[23]  J. Badimón,et al.  Pharmacology of thienopyridines: rationale for dual pathway inhibition , 2006 .

[24]  P. Carrascosa,et al.  Characterization of coronary atherosclerotic plaques by multidetector computed tomography. , 2006, The American journal of cardiology.

[25]  S. Frostick,et al.  Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial , 2007, Journal of thrombosis and haemostasis : JTH.

[26]  A. Avogaro,et al.  Endothelial progenitor cells in the natural history of atherosclerosis. , 2007, Atherosclerosis.

[27]  D. Grobbee,et al.  Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. , 2007, The New England journal of medicine.

[28]  R. Virmani,et al.  Elimination of neoangiogenesis for plaque stabilization: is there a role for local drug therapy? , 2007, Journal of the American College of Cardiology.

[29]  Colin Berry,et al.  Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. , 2007, JAMA.

[30]  J. Badimón,et al.  Plaque progression and regression in atherothrombosis , 2007, Journal of thrombosis and haemostasis : JTH.

[31]  D. Grobbee,et al.  Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia , 2007 .

[32]  J. Badimón,et al.  [Novel imaging techniques for quantifying overall atherosclerotic burden]. , 2007, Revista espanola de cardiologia.

[33]  V. Fuster,et al.  Downregulation of the Hemoglobin Scavenger Receptor in Individuals With Diabetes and the Hp 2-2 Genotype: Implications for the Response to Intraplaque Hemorrhage and Plaque Vulnerability , 2007, Circulation research.

[34]  A. Zwinderman,et al.  Simvastatin with or without ezetimibe in familial hypercholesterolemia. , 2008, The New England journal of medicine.

[35]  Borja Ibanez,et al.  HDL-cholesterol: is it really good? Differences between apoA-I and HDL. , 2008, Biochemical pharmacology.

[36]  Eric J. Eichhorn Simvastatin with or without ezetimibe in familial hypercholesterolemia. , 2008, The New England journal of medicine.

[37]  U. Hedner,et al.  Tissue factor and factor VIIa as therapeutic targets in disorders of hemostasis. , 2008, Annual review of medicine.

[38]  E. Tuzcu,et al.  Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. , 2008, JAMA.

[39]  Sameer Bansilal,et al.  Atherosclerosis Inflammation Imaging with 18F-FDG PET: Carotid, Iliac, and Femoral Uptake Reproducibility, Quantification Methods, and Recommendations , 2008, Journal of Nuclear Medicine.

[40]  Gemma Vilahur,et al.  Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis. , 2008, Journal of the American College of Cardiology.

[41]  J. Gillard,et al.  Utility of USPIO-enhanced MR imaging to identify inflammation and the fibrous cap: a comparison of symptomatic and asymptomatic individuals. , 2009, European journal of radiology.